COR-101 approved for first clinical study

COR-101 approved for first clinical study

by | Mar 16, 2021 | 2021, News

CORAT Therapeutics GmbH obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101. The study (ClinicalTrials.gov ID: NCT04674566) is a randomized, double-blind, placebo-controlled, parallel-group,...
Second financing round secured for the development of COR-101

Second financing round secured for the development of COR-101

by | Jan 12, 2021 | 2021, News

A second financing round was closed with NBank Capital, the investment company of NBank. Additional investors came from the private sector in Braunschweig. CORAT Therapeutics is in close coordination with the regulatory authorities and expects the green light for the...